中文
Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases
时间：2023-05-22
Used in this study:B-hIL4/hIL4RA mice
010-56967680
info@bbctg.com.cn